Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
June 16, 2021 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
May 28, 2021 08:30 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 07:30 ET | Wave Life Sciences USA, Inc.
Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program on track for...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
May 10, 2021 16:05 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
May 03, 2021 16:05 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 28, 2021 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
April 08, 2021 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
April 05, 2021 07:05 ET | uniQure Inc.
~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130 in Europe in the second half of 2021 ~ LEXINGTON, Mass....
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
March 29, 2021 16:05 ET | Wave Life Sciences USA, Inc.
mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Present at the Third Annual Stifel CNS Day
March 19, 2021 08:00 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...